Pulsatile vs Tonic Signalling

Many endocrine axes encode information in pattern rather than average concentration. A hypothalamic peptide released in bursts lets the target receptor resensitise between pulses, so the downstream cell reads frequency and amplitude as separate signals. Continuous exposure at the same time-averaged concentration removes that structure and drives the receptor through phosphorylation, arrestin recruitment, internalisation and downregulation. Pattern is a pharmacological variable in its own right.

Gonadotropin-releasing hormone is the definitive demonstration. Delivered in pulses roughly every 60 to 90 minutes it drives LH and FSH secretion, and pulsatile pump delivery is used to induce ovulation. Given continuously as a long-acting agonist such as leuprolide it produces a flare and then profound suppression, which is why one receptor pharmacology treats both infertility and prostate cancer. Parathyroid hormone runs the same way in reverse: intermittent daily teriparatide builds bone, while the continuous elevation of hyperparathyroidism resorbs it.

This decides whether a longer-acting analogue improves the mechanism or defeats it. For a replacement hormone acting on a tonic system, extending half-life is straightforwardly useful. For a secretagogue acting on an axis that reads pulses, the same modification can flatten exposure and abolish the effect it was meant to enhance — or deliberately exploit that abolition when suppression is the goal.

The common misreading is that more exposure means more effect, and that a longer-acting endocrine peptide is automatically better. The mirror error is the claim that a compound uniquely preserves natural pulsatility. That is a testable statement requiring frequent sampling of the downstream hormone across a full cycle, not something that follows from acting upstream of the pituitary.